Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2^nd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 11^th, at 11:30 a.m. PT / 2:30 p.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
[email protected]

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
[email protected]

You May Also Be Interested In

• Sagiss Strengthens Cross-Platform IT Expertise with Apple Technical Partner Status and Microsoft Support Services Designation
• Important Notice to Long-Term Shareholders of Badger Meter, Inc. (NYSE: BMI); First Solar, Inc. (NASDAQ: FSLR); GRAIL, Inc. (NASDAQ: GRAL); and Power Solutions International, Inc. (NASDAQ: PSIX): Grab
• CNL Employees Recognized by Canadian Nuclear Industry for Contributions to Canadian Society and Innovation in Science Education